The Latest Cardiac and Vascular News
Connected Cardiovascular Care Associates brings Arineta’s SpotLight scanner to its Rockwall location, broadening availability to the same technology they first brought to Dallas in 2023 Dallas, TX – October 29, 2025 – Connected Cardiovascular Care Associates (C3), a Dallas-based cardiology practice, is expanding its Arineta SpotLight installations that provide […]
Real-world evidence from the University of Virginia and University of Texas Medical Branch to be presented at American Heart Association (AHA) Scientific Sessions 2025 SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data demonstrating how Viz HCM enables faster, accurate detection […]
Company unveils patented technology designed to help maintain healthy blood flow during vascular procedures Backed by Sofinnova MD Start and led by experienced medtech entrepreneurs and cardiologists PARIS–(BUSINESS WIRE)–Tulyp Medical, a Paris-based startup developing a medical device for intelligent pressure-driven perfusion, emerged from stealth and announced it has submitted its […]
KIRKLAND, Wash., Nov. 04, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced its participation in the American Heart Association (AHA) Scientific Sessions 2025, to be held November 7–10 in New Orleans. Kestra’s participation will include a late-breaking science presentation titled Primary Results from the Post-Approval Study of a Next Generation Wearable Cardioverter Defibrillator System (ACE-PAS Trial), scheduled for Monday, November 10 at 8:44 a.m. CT in Session 211–213. The ASSURE® WCD Clinical Evaluation Post-Approval Study (ACE-PAS) is a contemporary study designed to evaluate real-world experience with a next-generation wearable cardioverter defibrillator system. Enrolling more than 20,000 patients across the U.S., ACE-PAS represents the largest prospective WCD study conducted to date. Primary endpoints include overall shock conversion success and inappropriate shock rate, with additional measures evaluating first shock conversion success, median daily wear time, and false alarm rate. The study’s selection for AHA’s late-breaking science program underscores how wearable defibrillator therapy, and data-driven insights, are advancing the way clinicians approach cardiac recovery and risk protection. “Being selected for a late-breaking presentation at AHA reflects both the clinical importance of the ACE-PAS study and the growing recognition of Kestra’s next-generation technology,” said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. “As the cardiac recovery landscape evolves, we’re redefining how wearable monitoring and therapy integrates with connected care and digital health innovation—advancing patient protection and delivering deeper clinical insight.” At booth #4617, attendees can explore the Kestra Cardiac Recovery System®, anchored by the ASSURE® Wearable Cardioverter Defibrillator, uniting proven patient protection with the clinical insights providers need to optimize guideline-directed medical therapy, implantable cardioverter defibrillator evaluation, and long-term recovery. In addition to the late-breaking presentation, Kestra will host live demonstrations and discussions throughout the meeting, featuring an immersive in-booth experience that highlights the company’s leadership in advancing connected, data-driven solutions for cardiac recovery. About Kestra Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. CONTACT: Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com
Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
FRANKLIN LAKES, N.J., Nov. 4, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective,…
DISRUPT BTK II one-year outcomes data demonstrate the strong safety profile and consistent effectiveness of the Shockwave Peripheral IVL system to help support wound healing and limb preservation LAS VEGAS, November 3, 2025 – Johnson & Johnson MedTech, a global leader in the field of circulatory restoration, today announced the one-year results […]
–The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to those who received only anticoagulation –Results of STORM-PE demonstrating superior efficacy of […]
PALO ALTO, Calif. and NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) — Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, announced today that the Company will present data from its anti-CD47 research at the American Heart Association (AHA) Annual Scientific Session 2025, taking place in New Orleans, Louisiana, November 7 – 10, 2025. AHA Abstracts Cardioprotection in a Rat Model of Ischemic Injury by a Novel Anti-CD47 Fusion Protein Presentation: Sa3080 (Heart Failure, Cardiomyopathy & Pulmonary Hypertension)Time: Saturday, November 8th at 10:30am CTPresenting Author: Pierre E. Signore, PhD Anti-CD47 Therapy Induces Early Macrophage-Specific Transcriptomic Changes Associated with the Resolution of Inflammation in a Murine Model of Atherosclerosis Presentation: Su4023 (Genetics and Genomics)Time: Sunday, November 9th at 11:30am CTPresenting Author: Derek Klarin, MD The posters will be available on the Bitterroot Bio website after the presentations. About Bitterroot BioBitterroot Bio, Inc. is a pioneer in the field of cardio-immunology, which investigates the interplay between the immune system and cardiovascular health. Bitterroot Bio’s research seeks to uncover critical roles that immune modulators play in the progression of cardiovascular disease. By targeting these diseases in this novel way, Bitterroot Bio’s mission is to transform the lives of patients suffering from cardiovascular diseases. For more information, please visit https://www.brbio.com or follow us on Facebook LinkedIn, or X. Media Contact: Pablo Fenton (Bitterroot Bio), media@brbio.com
Pivotal trial evaluated the safety and efficacy of the Hēlo™ Thrombectomy System for the removal of blood clots from the lungs MENLO PARK, Calif., Nov. 3, 2025 /PRNewswire/ — Dr. Andrew Klein, ENGULF National Co-Principal Investigator at Piedmont Hospital in Atlanta, today presented the…
Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country RAHWAY, N.J.–(BUSINESS WIRE)–The Merck Foundation announced today the launch of the Collaborative for Equity in Cardiac Care, a $22 million, five-year initiative aimed at enhancing […]
